transmembrane protein 59 likeGenealiases: BSMAP · C19orf4
Q-omics provides the consensus-scored TMEM59L profile across patient tissues and cancer cell-line models. TMEM59L expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TMEM59L is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, TMEM59L RNA expression shows 15,694 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, COAD, and TGCT as cancer lineages where TMEM59L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM59L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM59L survival associations across molecular data types. TMEM59L RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM59L RNA expression–survival associations across cancer types. High TMEM59L expression shows unfavorable associations in KIRP, ACC, BLCA, COAD and LUSC, but favorable associations in LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TMEM59L RNA expression.
This table summarizes TMEM59L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM59L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM59L shows lower tumor expression in COAD, KICH and KIRC and higher tumor expression in LUAD, THCA and LIHC. The COAD box plot shows higher TMEM59L RNA expression in normal versus tumor tissue (log2 FC = −1.574, t-test p < 0.001).
This table shows molecular features associated with TMEM59L in patient tissues and cancer cell lines. In patient samples, TMEM59L shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM59L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in CNS and SOFT_TISSUE.
